Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/141469
Full metadata record
DC FieldValueLanguage
dc.creatorGifre-Renom, L
dc.creatorSeras-Franzoso, J
dc.creatorRafael, D
dc.creatorAndrade, F
dc.creatorCano-Garrido, O
dc.creatorMartinez-Trucharte, F
dc.creatorUgarte-Berzal, E
dc.creatorMartens, E
dc.creatorBoon, L
dc.creatorVillaverde, A
dc.creatorOpdenakker, G
dc.creatorSchwartz, S
dc.creatorArís, A
dc.creatorGarcia-Fruitós, E
dc.date.accessioned2022-06-27T10:35:26Z-
dc.date.available2022-06-27T10:35:26Z-
dc.date.issued2020
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/10216/141469-
dc.description.abstractInclusion bodies (IBs) are protein nanoclusters obtained during recombinant protein production processes, and several studies have demonstrated their potential as biomaterials for therapeutic protein delivery. Nevertheless, IBs have been, so far, exclusively sifted by their biological activity in vitro to be considered in further protein-based treatments in vivo. Matrix metalloproteinase-9 (MMP-9) protein, which has an important role facilitating the migration of immune cells, was used as model protein. The MMP-9 IBs were compared with their soluble counterpart and with MMP-9 encapsulated in polymeric-based micelles (PM) through ionic and covalent binding. The soluble MMP-9 and the MMP-9-ionic PM showed the highest activity values in vitro. IBs showed the lowest activity values in vitro, but the specific activity evolution in 50% bovine serum at room temperature proved that they were the most stable format. The data obtained with the use of an air-pouch mouse model showed that MMP-9 IBs presented the highest in vivo activity compared to the soluble MMP-9, which was associated only to a low and a transitory peak of activity. These results demonstrated that the in vivo performance is the addition of many parameters that did not always correlate with the in vitro behavior of the protein of interest, becoming especially relevant at evaluating the potential of IBs as a protein-based nanomaterial for therapeutic purposes.
dc.description.sponsorshipThis work was funded by grants from INIA (MINECO, Spain) to A.A. and E.G.-F. (grant numbers RTA2012-00028-C02 and RTA2015-00064-C02) and AGAUR (grant number 2017SGR-229) to A.V and by grants (G.O.) and fellowships (E.U.-B. and L.B.) of the Research Foundation of Flanders (FWO-Vlaanderen). We are also indebted to CERCA Programme (Generalitat de Catalunya) and European Social Fund for supporting our research. L.G.R. received a pre-doctoral fellowship from INIA (FPI-INIA, MINECO), J.S.F. is supported by an “Asociación Española Contra el Cáncer (AECC)” post-doctoral fellowship, and E.G.F. received a post-doctoral fellowship from INIA (DOC-INIA). A.V. received an ICREA ACADEMIA award.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofPharmaceutics, vol.12(2):157
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThe biological potential hidden in inclusion bodies
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/pharmaceutics12020157
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/12/2/157
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-pharmaceutics12020157.pdf2.99 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons